Intracavernous injection therapy: analysis of results and complications.
Experience with 100 patients who used intracavernous injection therapy with a combination of papaverine with or without phentolamine for 29 months is analyzed in detail. The largest group of patients had vasculogenic erectile failure (56%). At the end of followup 50% of the patients were no longer performing injection. Those who discontinued injection therapy were slightly older and had more vasculogenic erectile failure. The nonfibrotic complications were mild in all instances and did not result in discontinuation of injection therapy. These complications consisted of small hematomas in 20.9% of the patients, mild discomfort in 13.6% and mild liver enzyme abnormalities in 9.8%. No episode of priapism or infection occurred during therapy. Fibrotic complications consisted of nodules or plaques, and correlated significantly with the number of months on injection and the number of injections. At 12 months the fibrotic complication rate was 31 +/- 8.6%. Our study suggests caution regarding the long-term complication rate of intracavernous injection therapy with these compounds and underscores the importance of routine followup examinations. While injection therapy is an effective form of treatment for erectile failure, it is not a satisfactory alternative for many patients and is associated with a significant fibrotic complication rate.
Lakin
M M
MM
Department of Biostatistics and Epidemiology, Cleveland Clinic Foundation, Ohio 44195-5041.
Montague
D K
DK
VanderBrug Medendorp
S
S
Tesar
L
L
Schover
L R
LR
D004359:Drug Therapy, Combination; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005355:Fibrosis; D006406:Hematoma / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010208:Papaverine / Q000009:adverse effects / Q000627:therapeutic use*; D010409:Penile Diseases / Q000139:chemically induced; D010410:Penile Erection / Q000187:drug effects*; D010413:Penis / Q000473:pathology; D010646:Phentolamine / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors
D010208:Papaverine; D010646:Phentolamine